Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States
This review synthesises fMRI and neuropharmacological evidence that both psychotic and psychedelic states feature thalamocortical dysconnectivity — notably thalamus–sensorimotor hyperconnectivity (linked to altered perception) and, in psychosis, thalamus–prefrontal hypoconnectivity (linked to cognitive deficits). It argues these shared patterns extend into cortico‑striatopallidothalamo‑cortical circuitry and discusses clinical implications and future research directions.
Authors
- Stefan Borgwardt
- Felix Müller
- Mihai Avram
Published
Abstract
Psychiatry has a well-established tradition of comparing drug-induced experiences to psychotic symptoms, based on shared phenomena such as altered perceptions. The present review focuses on experiences induced by classic psychedelics, which are substances capable of eliciting powerful psychoactive effects, characterized by distortions/alterations of several neurocognitive processes (e.g., hallucinations). Herein we refer to such experiences as psychedelic states. Psychosis is a clinical syndrome defined by impaired reality testing, also characterized by impaired neurocognitive processes (e.g., hallucinations and delusions). In this review we refer to acute phases of psychotic disorders as psychotic states. Neuropharmacological investigations have begun to characterize the neurobiological mechanisms underpinning the shared and distinct neurophysiological changes observed in psychedelic and psychotic states. Mounting evidence indicates changes in thalamic filtering, along with disturbances in cortico-striato-pallido-thalamo-cortical (CSPTC)-circuitry, in both altered states. Notably, alterations in thalamocortical functional connectivity were reported by functional magnetic resonance imaging (fMRI) studies. Thalamocortical dysconnectivity and its clinical relevance are well-characterized in psychotic states, particularly in schizophrenia research. Specifically, studies report hyperconnectivity between the thalamus and sensorimotor cortices and hypoconnectivity between the thalamus and prefrontal cortices, associated with patients' psychotic symptoms and cognitive disturbances, respectively. Intriguingly, studies also report hyperconnectivity between the thalamus and sensorimotor cortices in psychedelic states, correlating with altered visual and auditory perceptions. Taken together, the two altered states appear to share clinically and functionally relevant dysconnectivity patterns. In this review we discuss recent findings of thalamocortical dysconnectivity, its putative extension to CSPTC circuitry, along with its clinical implications and future directions.
Research Summary of 'Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States'
Introduction
Psychiatric research has long compared drug-induced experiences to psychotic symptoms because both involve altered perceptions and other neurocognitive changes. Classic serotonergic psychedelics (for example, psilocybin, DMT and LSD) produce altered states of consciousness by acting mainly at 5-HT2A receptors, eliciting phenomena such as visual hallucinations, ego-dissolution and other transient changes in perception and cognition. Psychotic states—acute phases of psychotic disorders—are characterised by impaired reality testing, more prominent auditory hallucinations and broader, often longer-lasting cognitive and negative symptoms. A theoretical account put forward to explain some shared features is the “thalamic filter” model, which proposes that disruptions in thalamic gating of sensory information—modulated by cortico‑striatal pathways and diverse neuromodulators—could produce sensory flooding and related symptoms in both conditions. This review by Selvaggi and colleagues examines recent neurobiological evidence for altered thalamocortical functional connectivity in psychotic and psychedelic states. The paper aims to compare and synthesise findings from human neuroimaging, animal work and multimodal studies to determine shared versus distinct patterns of thalamocortical dysconnectivity, to consider extensions to cortico‑striato‑pallido‑thalamo‑cortical (CSPTC) circuitry, and to outline clinical implications and directions for future research.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Topics
- Authors
- APA Citation
Avram, M., Rogg, H., Korda, A., Andreou, C., Müller, F., & Borgwardt, S. (2021). Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.706017
References (31)
Papers cited by this study that are also in Blossom
Osmond, H. · Annals of the New York Academy of Sciences (2010)
Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Corlett, P. R., Honey, G. D., Krystal, J. H. et al. · Neuropsychopharmacology (2010)
Nichols, D. E. · Pharmacology and Therapeutics (2004)
Nichols, D. E. · Pharmacological Reviews (2016)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Hirschfeld, T., Schmidt, T. T. · Journal of Psychopharmacology (2021)
Leptourgos, P., Fortier-Davy, M., Carhart-Harris, R. L. et al. · Schizophrenia Bulletin (2020)
Marek, G. J. · Current Topics in Behavioral Neurosciences (2018)
Show all 31 referencesShow fewer
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Gouzoulis-Mayfrank, E., Schreckenberger, M., Sabri, O. et al. · Neuropsychopharmacology (1999)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Lewis, C. R., Preller, K. H., Kraehenmann, R. et al. · NeuroImage (2017)
Vollenweider, F. X., Csomor, P. A., Knappe, B. et al. · Neuropsychopharmacology (2007)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Bershad, A. K., Preller, K. H., Lee, R. et al. · Biological Psychiatry (2020)
Luppi, A. I., Carhart-Harris, R. L., Roseman, L. et al. · NeuroImage (2021)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Sanz, C., Zamberlan, F., Erowid, E. et al. · Frontiers in Neuroscience (2018)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)
Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)
Höflich, A., Hahn, A., Küblböck, M. et al. · International Journal of Neuropsychopharmacology (2015)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)
Cited By (9)
Papers in Blossom that reference this study
Mäki-Marttunen, V. · Communications Biology (2026)
Coleman, J. A., Shinozuka, K., Tromm, R. et al. · Human Brain Mapping (2025)
Avram, M., Fortea, L., Wollner, L. et al. · Molecular Psychiatry (2024)
Bagdasarian, F. A., Hansen, H. D., Chen, J. et al. · ACS Chemical Neuroscience (2024)
Avram, M., Müller, F., Preller, K. H. et al. · Biological Psychiatry (2024)
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Pizzi, S. D., Chiacchiaretta, P., Sestieri, C. et al. · NeuroImage (2023)
Girn, M., Rosas, F. E., Daws, R. E. et al. · Trends in Cognitive Sciences (2023)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.